USP and EDQM publish stakeholder-forum outcome, committing to deeper pharmacopoeial harmonisation and reliance
Verified against the EDQM primary (published 27 Jul 2026); underlying forum 6 May 2026. Soft/direction-of-travel - authored as the opening lead, not a compliance event.
For BA/QC and regulatory-affairs teams, USP-EDQM convergence is the quiet infrastructure that determines whether an analytical method, specification or monograph written for one market travels to another without re-work. Prospective co-development of monographs narrows the gap that forces duplicate method validation and dual-compendial testing; deeper reliance signals that a specification accepted by one authority is more likely to be accepted by the other. It is a direction-of-travel signal rather than a dated compliance action - no new monograph or method is mandated here - but it frames how compendial requirements will harmonise and where duplicated testing burden should fall over time.
Pharmacopoeial harmonisation, regulatory reliance, monograph co-development